Mcl-1 is a potential therapeutic target in multiple types of cancer

Cellular and Molecular Life Sciences

Volumn 66, Issue 8, 2009, Pages 1326-1336

  Akgul, C ^a  

^a ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Bcl 2 family; Cancer; Mcl 1; Therapeutic

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9 DIEN 28 OIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 6 (2,6 DICHLOROPHENYL) 2 (4 FLUORO 3 METHYLANILINO) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BH3 PROTEIN; BIM PROTEIN; CYTOCHROME C; DASATINIB; DEXAMETHASONE; EPIGALLOCATECHIN GALLATE; ETODOLAC; FLAVOPIRIDOL; HOMOHARRINGTONINE; IBUPROFEN; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL X; PROTEIN BID; PROTEIN MCL 1; PSEUDOMONAS EXOTOXIN; PUMA PROTEIN; RESVERATROL; ROSCOVITINE; SDX 101; SORAFENIB; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALTERNATIVE RNA SPLICING; APOPTOSIS; CANCER THERAPY; CELL STRAIN HCT116; CELL SURVIVAL; CHROMOSOME 1Q; CHRONIC MYELOID LEUKEMIA; DRUG INHIBITION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MULTIPLE MYELOMA; NEOPLASM; OLIGOMERIZATION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION;

APOPTOSIS REGULATORY PROTEINS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 67349136004     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-008-8637-6     Document Type: Review

References (98)

1. Kerr, J. F., Wyllie, A. H. and Currie, A. R. (1972) Apoptosis : A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257.
2. Sprick, M. R. and Walczak, H. (2004) The interplay between the Bcl-2 family and death receptor-mediated apoptosis. Biochim. Biophys. Acta 1644, 125-132.
3. Adams, J. M, and Cory, S. (1998) The Bcl-2 protein family: Arbiters of cell survival. Science 281, 1322-1326.
4. Adams, J. M. and Cory, S. (2001) Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26, 61-66.
5. Petros, A. M., Olejniczak, E. T. and Fesik, S. W. (2004) Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83-94.
6. Adams, J. M. and Cory, S. (2007) Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr. Opin. Immunol. 19, 488-496.
7. Green, D. R. and Reed, J. C. (1998) Mitochondria and apoptosis. Science 281, 1309-1312.
8. Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P. and Craig, R. W. (1993) MCLl, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA 90, 3516-3520.
9. Krajewski, S., Bodrug, S., Krajewska, M., Shabaik, A., Gascoyne, R., Berean, K. and Reed, J. C. (1995) Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am. J. Pathol. 146, 1309-1319.
10. Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Zhang, X. D., Thompson, J. F. and Hersey, P. (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Mod. Pathol, 20, 416-426.
11. Itoh, T, Itoh, A. and Pleasure D. (2003) Bcl-2-related protein family gene expression during oligodendroglial differentiation. J. Neurochem. 85,1500-1512.
12. Bingle, C. D., Craig, R. W., Swales, B. M., Singleton, V., Zhou, P. and Whyte, M. K. (2000) Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J. Biol. Chem. 275,22136-22146.
13. Akgul, C., Moulding, D. A., White, M. R. and Edwards, S. W. (2000) In vivo localisation and stability of human Mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Lett. 478, 72-76.
14. Weng, C., Li, Y., Xu, D., Shi, Y and Tang, H. (2005) Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J. Biol. Chem. 280, 10491-10500.
15. Kobayashi, S., Lee, S. H., Meng, X. W., Mott, J. L., Bronk, S. F., Werneburg, N. W., Craig, R. W., Kaufmann, S. H. and Gores, G. J. (2007) Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J. Biol. Chem. 282,18407-18417.
16. Ding, Q., He, X., Hsu, J. M., Xia, W., Chen, C. T., Li, L. Y., Lee, D. F., Liu, J. G., Zhong, Q., Wang, X. and Hung, M. C. (2007) Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol. Cell. Biol. 27,4006-4017.
17. Ding, Q., Huo, L., Yang, J. Y., Xia, W., Wei, Y., Liao, Y., Chang, C. J., Yang, Y., Lai, C. C., Lee, D. F., Yen, C. J., Chen, Y J., Hsu, J. M., Kuo, H. P., Lin, C. Y., Tsai, F. J., Li, L. Y., Tsai, C. H. and Hung, M. C. (2008) Down-regulation of myeloid cell leukemia1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 68, 6109-6117.
18. Shimazu, T., Degenhardt, K., Nur-E-Kamal, A., Zhang, J., Yoshida, T., Zhang, Y., Mathew, R., White, E. and Inouye, M. (2007) NBK/BIK antagonizes MCL-I and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev. 21, 929-941.
19. Han, J., Goldstein, L. A., Hou, W. and Rabinowich, H. (2007) Functional linkage between NOXA and Bim in mitochondrial apoptotic events. J. Biol. Chem. 282, 16223-16231.
20. Clohessy, J. G., Zhuang, J., de Boer, J., Gil-Gómez, G. and Brady, H. J. (2006) Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281, 5750-5759.
21. Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M. and Huang, D. C. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393-403.
22. Willis, S. N., Chen, L.,Dewson,G.,Wei, A., Naik, E., Fletcher, J. I.,Adams, J. M. and Huang,D. C. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 19, 1294-1305.
23. Kim, H., Rafiuddin-Shah, M., Tu, H. C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J. and Cheng, E. H. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348-1358.
24. Isomoto, H., Kobayashi, S., Werneburg, N. W., Bronk, S. F., Guicciardi, M. E., Frank, D. A. and Gores, G. J. (2005) Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42, 1329-1338.
25. Aichberger, K. J., Mayerhofer, M., Krauth, M. T., Skvara, H., Florian, S., Sonneck, K., Akgul, C., Derdak, S., Pickl, W. F., Wacheck, V., Selzer, E., Monia, B. P., Moriggl, R., Valent, P. and Sillaber, C. (2005) Identification of mcl-1 as a BCR/ABLdependent target in chronic myeloid leukemia (CML): Evidence for cooperative antileukemic effects of imatinib and mcl1 antisense oligonucleotides. Blood 105, 3303-3311.
26. Wang, J. M., Chao, J. R., Chen, W., Kuo, M. L., Yen, J. J. and Yang-Yen, H. F. (1999) The antiapoptotic gene mcl-1 is upregulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell Biol. 19, 6195-6206.
27. Wang, J. M., Lai, M. Z. andYang-Yen, H. F. (2003) Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol. Cell Biol. 23, 1896-1909.
28. Jiang, C. C., Lucas, K., Avery-Kiejda, K. A., Wade, M., deBock,C. E., Thorne,R. F., Allen, J.,Hersey, P. and Zhang,X. D. (2008) Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res. 68, 6708-6717.
29. Piret, J. P.,Minet, E.,Cosse, J. P., Ninane,N., Debacq,C.,Raes, M. and Michiels,C. (2005) Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J. Biol. Chem. 280, 9336-9344.
30. Vickers,E.R., Kazsa, A.,Kurnaz, I. A., Seifert, A.,Zeef, L.A., O'Donnell, A., Hayes, A. and Sharrocks, A. D. (2004) Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death. Mol. Cell Biol. 24, 10340-10351.
31. Marriott, H. M., Bingle, C. D., Read, R. C., Braley, K. E., Kroemer, G., Hellewell, P. G., Craig, R.W.,Whyte, M. K. and Dockrell, D. H. (2005) Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J. Clin. Invest. 115, 359-368.
32. Moulding, D. A., Akgul, C., Derouet, M., White, M. R. and Edwards, S. W. (2001) BCL-2 family expression in human neutrophils during delayed and accelerated apoptosis. J. Leukoc. Biol. 70, 783-792.
33. Mott, J. L., Kobayashi, S., Bronk, S. F. and Gores, G. J. (2007) mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26, 6133-6140.
34. Subramaniam,D., Natarajan,G., Ramalingam, S., Ramachandran, I.,May, R., Queimado, L., Houchen, C.W. and Anant, S. (2008) Translation inhibition during cell cycle arrest and apoptosis: Mcl-1 is a novel target for RNA binding protein CUGBP2. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1025-1032.
35. Mills, J. R., Hippo,Y., Robert, F., Chen, S. M.,Malina, A., Lin, C. J., Trojahn, U.,Wendel, H. G., Charest, A., Bronson, R. T., Kogan, S. C., Nadon, R., Housman, D. E., Lowe, S. W. and Pelletier, J. (2008) mTORC1 promotes survival through translational control of Mcl-1. Proc. Natl. Acad. Sci. USA 105, 10853-10858.
36. Domina, A.M., Vrana, J. A., Gregory,M. A., Hann, S. R. and Craig, R. W. (2004) MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23, 5301-5315.
37. Maurer, U., Charvet, C., Wagman, A. S., Dejardin, E. and Gren, D. R. (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 21, 749-760.
38. Inoshita, S., Takeda, K., Hatai, T., Terada, Y., Sano,M., Hata, J., Umezawa, A. and Ichijo, H. (2002) Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J. Biol. Chem. 277, 43730-43734.
39. Derouet, M., Thomas, L., Cross,A., Moots, R. J. and Edwards, S. W. (2004) Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J. Biol. Chem. 279, 26915-26921.
40. Zhong, Q., Gao, W., Du, F. and Wang, X. (2005) Mule/ARFBP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121, 1085-1095.
41. Michels, J., O'Neill, J. W., Dalman, C. L., Mouzakiti, A., Habens, F., Brimmell, M., Zhang, K. Y., Craig, R. W., Marcusson, E. G., Johnson, P. W. and Packham, G. (2004) Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspasemediated cleavage. Oncogene 23, 4818-4827.
42. Derenne, S., Monia, B.,Dean,N. M., Taylor, J. K., Rapp,M. J., Harousseau, J. L., Bataille, R. and Amiot, M. (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100, 194-199.
43. Cho-Vega, J. H., Rassidakis, G. Z., Admirand, J. H., Oyarzo, M., Ramalingam, P., Paraguya, A.,McDonnell, T. J., Amin, H. M. and Medeiros, L. J. (2004) MCL-1 expression in B-cell non-Hodgkin's lymphomas. Hum. Pathol. 35, 1095-1100.
44. Sieghart,W., Losert, D., Strommer, S., Cejka, D., Schmid, K., Rasoul-Rockenschaub, S., Bodingbauer, M., Crevenna, R., Monia, B. P., Peck-Radosavljevic, M. and Wacheck, V. (2006) Mcl-1 overexpression in hepatocellular carcinoma:Apotential target for antisense therapy. J. Hepatol. 44, 151-157.
45. Nguyen, M., Marcellus, R. C., Roulston, A., Watson, M., Serfass, L., Murthy Madiraju, S. R., Goulet, D., Viallet, J., Bélec, L., Billot, X., Acoca, S., Purisima, E., Wiegmans, A., Cluse, L., Johnstone, R. W., Beauparlant, P. and Shore, G. C. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 104, 19512-19517.
46. Hussain, S. R.,Cheney,C.M., Johnson, A. J., Lin,T. S.,Grever, M. R.,Caligiuri, M. A., Lucas,D.M. and Byrd, J.C. (2007) Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin. Cancer Res. 13, 2144-2150.
47. Paoluzzi, L.,Gonen, M.,Gardner, J.R., Mastrella, J.,Yang,D., Holmlund, J., Sorensen, M., Leopold, L., Manova, K., Marcucci, G., Heaney, M. L. and O'Connor, O. A. (2008) Targeting Bcl-2 family members with the BH3 mimeticAT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Blood 111, 5350-5358.
48. Andersson, Y., Juell, S. and Fodstad, Ø. (2004) Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int. J. Cancer 112, 475-483.
49. Chetoui, N., Sylla, K., Gagnon-Houde, J. V., Alcaide-Loridan, C., Charron, D., Al-Daccak, R. and Aoudjit, F. (2008) Downregulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to Fas-mediated apoptosis. Mol. Cancer Res. 6, 42-52.
50. Wei, S. H., Dong, K., Lin, F., Wang, X., Li, B., Shen, J. J., Zhang, Q., Wang, R. and Zhang, H. Z. (2008) Inducing apoptosis and enhancing chemosensitivity to Gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother. Pharmacol. 62, 1055-1064.
51. Allen, T. M., Cheng, W. W., Hare, J. I. and Laginha, K. M. (2006) Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med. Chem. 6, 513-523.
52. Kuroda, J., Kamitsuji, Y., Kimura, S., Ashihara, E., Kawata, E., Nakagawa, Y., Takeuichi, M., Murotani, Y., Yokota, A., Tanaka, R., Andreeff, M., Taniwaki, M. and Maekawa, T. (2008) Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules,Mcl-1, XIAP, and beta-catenin. Int. J. Hematol. 87, 507-515.
53. Duan, Z., Ames, R. Y., Ryan, M., Hornicek, F. J., Mankin, H. and Seiden, M. V. (2008) CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multidrug resistant ovarian cancer cells. Cancer Chemother. Pharmacol. (Epub ahead of print).
54. Tang, R., Faussat, A. M.,Majdak, P.,Marzac, C., Dubrulle, S., Marjanovic, Z., Legrand, O. and Marie, J. P. (2006) Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells. Mol. Cancer Ther. 5, 723-731.
55. Turkson, J. (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8, 409-422.
56. Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J. and Jove R. (2006) Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis ofmalignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5, 621-629.
57. Thyrell, L., Arulampalam, V., Hjortsberg, L., Farnebo, M., Grandér, D. and Pokrovskaja Tamm, K. (2007) Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp.Cell Res. 313, 4015-4024.
58. Nam, S., Williams, A., Vultur, A., List, A., Bhalla, K., Smith, D., Lee, F. Y. and Jove, R. (2007) Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 6, 1400-1405.
59. Huang, M., Dorsey, J. F., Epling-Burnette, P. K., Nimmanapalli, R., Landowski, T. H.,Mora, L. B., Niu, G., Sinibaldi, D., Bai, F., Kraker, A., Yu, H., Moscinski, L., Wei, S., Djeu, J., Dalton, W. S., Bhalla, K., Loughran, T. P., Wu, J. and Jove, R. (2002) Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth ofCMLcells. Oncogene 21, 8804-8816.
60. Mow, B. M., Chandra, J., Svingen, P. A., Hallgren, C. G., Weisberg, E., Kottke, T. J., Narayanan, V. L., Litzow, M. R., Griffin, J. D., Sausville, E. A., Tefferi, A. and Kaufmann, S. H. (2002) Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 99, 664-671.
61. MacCallum, D. E., Melville, J., Frame, S.,Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P. and Gren, S. R. (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase IIdependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399-5407.
62. Gojo, I., Zhang, B. and Fenton, R. G. (2002) The cyclindependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 8, 3527-3538.
63. Rahmani, M., Davis, E. M., Bauer, C., Dent, P. and Grant, S. (2005) Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J. Biol. Chem. 280, 35217-35227.
64. Maggio, S. C., Rosato, R. R., Kramer, L, B., Dai, Y., Rahmani, M., Paik, D. S., Czarnik, A. C., Payne, S. G., Spiegel, S. and Grant, S. (2004) The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 64, 2590-2600.
65. Ryu, J. K., Lee, W. J., Lee, K. H., Hwang, J. H., Kim, Y. T., Yoon, Y. B. and Kim, C. Y. (2006) SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.Cancer Lett. 237, 143-154.
66. Kim, M. H. (2008) Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG+ ibuprofen. J. Cell Biochem. 104, 1491-1499.
67. Yasui, H., Hideshima, T., Hamasaki, M., Roccaro, A. M., Shiraishi,N.,Kumar, S.,Tassone, P., Ishitsuka, K.,Raje,N.,Tai, Y. T., Podar, K., Chauhan, D., Leoni, L. M., Kanekal, S., Elliott, G., Munshi, N. C. and Anderson KC. (2005) SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood 106, 706-712.
68. Mercatante,D.R., Bortner, C.D., Cidlowski, J. A. andKole,R. (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J. Biol. Chem. 276, 16411-16417.
69. Mercatante, D. R., Sazani, P. and Kole, R. (2001) Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr. Cancer Drug Targets 1, 211-230.
70. Akgul, C., Moulding, D. A. and Edwards, S. W. (2004) Alternative splicing of Bcl-2-related genes: Functional consequences and potential therapeutic applications. Cell. Mol. Life Sci. 61, 2189-2199.
71. Wang,Y. F., Jiang, C. C., Kiejda, K. A.,Gillespie, S., Zhang, X. D. and Hersey, P. (2007) Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin. Cancer Res. 13, 4934-4942.
72. Pan, J., Quintás-Cardama, A., Manshouri, T., Giles, F. J., Lamb, P., Tefferi, A., Cortes, J., Kantarjian,H. andVerstovsek, S. (2007) The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1. Leukemia 21, 1395-1404.
73. Dias, N. and Stein, C. A. (2002) Antisense oligonucleotides: Basic concepts and mechanisms. Mol. Cancer Ther. 1, 347-355.
74. Putral, L. N., Gu, W. and McMillan, N. A. (2006) RNA interference for the treatment of cancer. Drug News Perspect. 19, 317-324.
75. Moulding,D.A., Giles,R.V., Spiller,D.G.,White,M.R.,Tidd, D. M. and Edwards, S.W. (2000) Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells. Blood 96, 1756-1763.
76. Aichberger, K. J.,Mayerhofer,M., Gleixner,K. V., Krauth, M. T., Gruze, A., Pickl, W. F., Wacheck, V., Selzer, E., Mllauer, L., Agis, H., Sillaber, C. and Valent, P. (2007) Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: Inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 109, 3031-3041.
77. Labi, V., Grespi, F., Baumgartner, F. and Villunger, A. (2008) Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy. Cell Death Differ. 15, 977-987.
78. Mohammad, R., Giri, A. and Goustin, A. S. (2008) Smallmolecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. Recent Patents Anticancer Drug Discov. 3, 20-30.
79. Oltersdorf,T., Elmore, S.W., Shoemaker,A.R., Armstrong,R. C., Augeri, D. J. and Belli, B. A. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
80. Chen, S., Dai, Y., Harada, H., Dent, P. and Grant, S. (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 67, 782-791.
81. Lin, X., Morgan-Lappe, S., Huang, X., Li, L., Zakula, D. M., Vernetti, L. A., Fesik, S.W. and Shen, Y. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26, 3972-3979.
82. Kang,M.H.,Wan, Z.,Kang,Y.H., Sposto,R. and Reynolds,C. P. (2008) Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J. Natl. Cancer Inst. 100, 580-595.
83. Wang, Z., Song,W., Aboukameel, A.,Mohammad, M.,Wang, G., Banerjee, S., Kong, D., Wang, S., Sarkar, F. H. and Mohammad, R. M. (2006)TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int. J. Cancer. 123, 958-966.
84. Prakesch, M.,Denisov,A.Y., Naim,M., Gehring,K. and Arya, P. (2008) The discovery of small molecule chemical probes of Bcl-X(L) and Mcl-1. Bioorg. Med. Chem. 16, 7443-7449.
85. Tang,G.,Yang,C.Y.,Nikolovska-Coleska, Z.,Guo, J., Qiu, S., Wang, R.,Gao,W.,Wang,G., Stuckey, J., Krajewski, K., Jiang, S.,Roller, P. P. andWang, S. (2007) Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. J.Med. Chem. 50, 1723-1726.
86. Tang, G., Ding, K., Nikolovska-Coleska, Z., Yang, C. Y., Qiu, S., Shangary, S., Wang, R., Guo, J., Gao, W., Meagher, J., Stuckey, J., Krajewski, K., Jiang, S., Roller, P. P. and Wang, S. (2007) Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. J. Med. Chem. 50, 3163-3166.
87. Etxebarria, A., Landeta, O., Antonsson, B. and Basañez, G. (2008) Regulation of antiapoptotic MCL-1 function by gossypol: Mechanistic insights from in vitro reconstituted systems. Biochem Pharmacol. 76, 1563-1576.
88. Arnold, A. A., Aboukameel, A., Chen, J., Yang, D.,Wang, S., Al-Katib, A. and Mohammad, R. M. (2008) Preclinical studies of Apogossypolone: A new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model. Mol. Cancer 7, 20.
89. Trudel, S., Li, Z. H., Rauw, J., Tiedemann, R. E., Wen, X. Y. and Stewart, A. K. (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109, 5430-5438.
90. Lee, E. F., Czabotar, P. E., van Delft, M. F., Michalak, E. M., Boyle,M. J.,Willis, S.N., Puthalakath, H.,Bouillet, P.,Colman, P. M., Huang, D. C. and Fairlie, W. D. (2008) A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J. Cell Biol. 180, 341-355.
91. Lasithiotakis, K. G., Sinnberg, T.W., Schittek, B., Flaherty, K. T., Kulms, D., Maczey, E., Garbe, C. and Meier, F. E. (2008) Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 128, 2013-2023.
92. Hahn, M., Li,W., Yu, C., Rahmani, M., Dent, P. and Grant, S. (2005) Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol. Cancer Ther. 4, 457-470.
93. Qin, J. Z., Xin, H., Sitailo, L.A., Denning,M. F. and Nickoloff, B. J. (2006) Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA. Cancer Res. 66, 9636-9645.
94. Tahir, S. K., Yang, X., Anderson,M. G., Morgan-Lappe, S. E., Sarthy, A. V., Chen, J., Warner, R. B., Ng, S. C., Fesik, S. W., Elmore, S.W., Rosenberg, S.H. and Tse, C. (2007) Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res. 67, 1176-1183.
95. Boucher, M. J., Morisset, J., Vachon, P. H., Reed, J. C., Lainé, J. and Rivard, N. (2000) MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355-369.
96. O'Kane S. L., Pound R. J., Campbell A., Chaudhuri N., Lind M, J. and Cawkwell L. (2006) Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol. 45, 449-453.
97. Fleischer, B., Schulze-Bergkamen, H., Schuchmann, M., Weber, A., Biesterfeld, S., Müller, M., Krammer, P. H. and Galle, P. R. (2006) Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int. J. Oncol. 28, 25-32.
98. Wacheck, V., Cejka, D., Sieghart, W., Losert, D., Strommer, S., Crevenna, R., Monia, B. P. and Selzer, E. (2006) Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol. Ther. 5, 1348-1354.